- CollPlant Biotechnologies (CLGN, Financial) secures a European patent for its collagen-based formulations.
- The patent, valid until 2041, covers soft tissue fillers and regenerative breast implant technology.
- This development solidifies CollPlant's position in markets projected to be worth over $9 billion combined.
CollPlant Biotechnologies (CLGN) has announced the successful securing of a European patent allowance for its innovative collagen-based formulations designed for use in soft tissue fillers and implants. This patent is critical in bolstering the company's market presence, as it covers both injectable fillers and regenerative breast implant technology made with their proprietary recombinant human collagen (rhCollagen).
The patent is valid until 2041, providing CollPlant with a 17-year period of market exclusivity across Europe. This strategic move is expected to give the company a competitive edge in two lucrative markets: the injectable soft-tissue filler market, estimated at over $6 billion, and the breast implant market, valued at more than $3 billion.
The technology specifically encapsulated within the patent includes a 3D biocompatible and degradable soft tissue implant featuring a bioprinted scaffold and an injectable filler. Each component is based on CollPlant's non-animal-derived collagen, which could pave the way for safer and more effective aesthetic solutions.
CollPlant's Chief Executive Officer, Yehiel Tal, highlighted the importance of this patent in furthering the company's strategic ambitions to expand its unique rhCollagen technology into high-value markets. This patented technology platform is set to serve both the aesthetic and reconstructive medicine sectors, offering potential partnerships and licensing deals with leading players in the medical device industry.
